Drug Profile
GSK 679586
Alternative Names: 679586; GSK679586; GSK679586ALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 06 May 2010 GlaxoSmithKline completes enrolment in the phase II 106870 trial in Asthma in USA, South Africa, European Union & Norway
- 21 Jan 2008 Phase I development is ongoing
- 01 Nov 2006 Phase-I clinical trials in Asthma in Australia (IV-infusion)